Katty Zeven
YOU?
Author Swipe
View article: Immune modulation following α and β <sup>−</sup> radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model
Immune modulation following α and β <sup>−</sup> radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model Open
α- and β--emitting radionuclides targeting human fibroblast activation protein-α (hFAP) are under investigation for cancer therapy. In prior work, analysis of the tumor microenvironment 24 h after therapy completion indicated th…
View article: Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers
Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers Open
View article: Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity Open
Background Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of the overexpression of B7-H3 …
View article: Generation and Characterization of Novel Pan‐Cancer Anti‐uPAR Fluorescent Nanobodies as Tools for Image‐Guided Surgery
Generation and Characterization of Novel Pan‐Cancer Anti‐uPAR Fluorescent Nanobodies as Tools for Image‐Guided Surgery Open
Fluorescence molecular imaging plays a vital role in image‐guided surgery. In this context, the urokinase plasminogen activator receptor (uPAR) is an interesting biomarker enabling the detection and delineation of various tumor types due t…
View article: Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy
Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy Open
Summary The evolving landscape of cancer immunotherapy has revolutionized cancer treatment. However, the dynamic tumor microenvironment has led to variable clinical outcomes, indicating a need for predictive biomarkers. Noninvasive nuclear…
View article: In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells
In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells Open
View article: Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT Open
Introduction T cell Ig and ITIM domain receptor (TIGIT) is a next-generation immune checkpoint predominantly expressed on activated T cells and NK cells, exhibiting an unfavorable prognostic association with various malignancies. Despite t…
View article: Emerging applications of nanobodies in cancer therapy
Emerging applications of nanobodies in cancer therapy Open
View article: Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade Open
View article: Development of LAG-3 nanobodies as potent cancer imaging tracers
Development of LAG-3 nanobodies as potent cancer imaging tracers Open
View article: Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use Open
Immune checkpoint inhibition (ICI) is a promising cancer therapy, which has progressed rapidly from a preclinical concept to clinical implementation. Commonly considered targets in ICI are CTLA-4, PD-1/PD-L1, and LAG-3, and the list grows.…